According to the available limited clinical evidence obtained from retrospective studies, combined therapy with brigatinib and cetuximab may be beneficial, and was recommended for NSCLC patients with T790M in cis with C797S EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.